Investing.com -- 在公司宣布其RAMP 201二期临床试验的主要分析数据发表在《临床肿瘤学杂志》(Journal of Clinical Oncology)后,Verastem Inc (NASDAQ:VSTM)股价上涨3.5%。 已发表的数据显示,avutometinib联合defactinib治疗复发性低级别浆液性卵巢癌(LGSOC)的所有患者中,确认的总体响应率为31%。在...
Source LinkInvesting.com -- 在公司宣布其RAMP 201二期临床试验的主要分析数据发表在《临床肿瘤学杂志》(Journal of Clinical Oncology)后,Verastem Inc (NASDAQ:VSTM)股价上涨3.5%。 已发表的数据显示,avutometinib联合defactinib治疗复发性低级别浆液性卵巢癌(LGSOC)的所有患者中,确认的总体响应率为31%。在...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.